In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
March 8, 2016
-
BUSINESS Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
March 7, 2016
-
REGULATORY Sovaldi, Harvoni Face 31.7% Price Cut under “Huge Seller” Re-Pricing: MHLW
March 4, 2016
-
REGULATORY FY2016 NHI Pricing Reform to Bring “1 Victory, 1 Defeat, 1 Draw” for Industry: MHLW Official
March 3, 2016
-
BUSINESS Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
March 2, 2016
-
BUSINESS Drug Wholesalers’ Inventory Margins Likely to Diminish for FY2016 Price Revision
March 1, 2016
-
BUSINESS PCSK9 Inhibitor Repatha Expected to Debut this Spring, with Competing Products to Follow
February 29, 2016
-
BUSINESS Torii to Expand Sales Force to 570 by FY2018; Will Actively Seek Acquisitions, Alliances
February 26, 2016
-
BUSINESS Takeda, ASKA Announce Deal on Ecard Authorized Generic
February 25, 2016
-
REGULATORY Possible Price Slash for Big-Sellers Looms as 2017 Tax Hike Nears; All Eyes on Opdivo
February 24, 2016
-
BUSINESS Zosyn Generics Face Labeling Revisions, Shipment Halts over False-Positive Concerns
February 23, 2016
-
BUSINESS Israel’s Pluristem in Hunt for Japan Partner to Market Placenta-Based Cell Therapies
February 22, 2016
-
BUSINESS Ferring Revs Up for Full-Fledged Foray into GI Market, Eyes Japan Sales of €300 Million in 2020
February 19, 2016
-
BUSINESS Sakigake: Now and Future (3) - Astellas’s FLT3 Inhibitor for AML Receives Designation, but Other Companies Trailing
February 19, 2016
-
REGULATORY Next Invitation for Sakigake Pathway Might Not Happen Until FY2017, Designations Likely to Decrease: Official
February 18, 2016
-
TRENDS Multiple Authorized Generics Get Approval towards June Listing as Pharmas See Opportunities
February 17, 2016
-
REGULATORY 22 Firms Win Approvals for Zyprexa Generics for June Listing; Kipres AGs Also OK’ed
February 16, 2016
-
TRENDS Japan Drug Makers Foresee 6% Sales Growth in FY2015: Jiho Tally
February 15, 2016
-
REGULATORY Chuikyo Submits Recommendation for FY2016 Reimbursement Policy Reform, New Generic Incentive for Clinics Already Questioned
February 12, 2016
-
BUSINESS Sakigake: Now and Future (2) - Shionogi Aims to Submit Application for Novel Flu Drug as Early as FY2017
February 12, 2016
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…